Deana Freeman, NP
Gerontology · Florence, SCNPI 1225498447
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 40.0% of the total. 2025 is the largest year on record at $988, 2.5 times the $388 reported in 2021.
Across 144 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$876
- Amgen$204
- Novo Nordisk$155
- GSK$155
- Dexcom, Inc.$73
- Viiv Healthcare Company$72
- plus $652 from 23 others
What the payments were for
- Food & beverage$2,187100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $876 |
| Amgen | 13 | $204 |
| Novo Nordisk | 10 | $155 |
| GSK | 10 | $155 |
| Dexcom, Inc. | 4 | $73 |
| Viiv Healthcare Company | 3 | $72 |
| Novartis | 4 | $67 |
| Abbott | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $44 |
| Pfizer | 2 | $38 |
| Exact Sciences | 2 | $34 |
| Bayer | 2 | $32 |
| Shield Therapeutics Inc | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $29 |
| Merck | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$2,187 in reported general payments places this provider in the 70th percentile of 137 gerontology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $122,028 |
| JardianceEmpagliflozin | 73 | $75,139 |
| LinzessLinaclotide | 83 | $72,503 |
| JanuviaSitagliptin Phosphate | 44 | $49,308 |
| EliquisApixaban | 53 | $40,789 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $32,524 |
| MounjaroTirzepatide | 27 | $27,885 |
| TrulicityDulaglutide | 20 | $27,105 |
| VraylarCariprazine Hcl | 12 | $16,268 |
| TrintellixVortioxetine Hydrobromide | 31 | $16,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,808 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,322 |
| Dexlansoprazole DrDexlansoprazole | 19 | $6,456 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,005 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $155 | $122,028122 claims |
| AbbVieLinzess, Vraylar | $876 | $88,77195 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $15 | $80,14384 claims |
| Lilly USA, LLCMounjaro, Trulicity | $44 | $54,99047 claims |
| MerckJanuvia | $28 | $49,30844 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $155 | $45,33264 claims |
| PfizerEliquis | $38 | $40,78953 claims |
| AstraZenecaBreztri Aerosphere | $20 | $10,32216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 137 gerontology providers in South Carolina.
Other gerontology in Florence
- Amanda CieluchFlorence$2K
- Jesse KasitzFlorence$1K
- Timothy MalinowskiGreenville$49K
- Ann ShattuckNorth Charleston$15K
- Erin SullivanColumbia$13K
- Nicole FerroniCharleston$11K
- Kathryn RarickGreenville$10K
- Ryan BakerColumbia$9K
- Rachael WillsGreenville$8K
- Karen CainGreenville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.